Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$65.36 USD
+2.61 (4.16%)
Updated May 28, 2024 04:00 PM ET
After-Market: $65.34 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Viking Therapeutics, Inc. [VKTX]
Reports for Purchase
Showing records 61 - 80 ( 211 total )
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
VK0214 Administrative Hold After FDA Back and Forth
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Novel Dual GLP-1/GIP Receptor Agonist Jumps Into Humans;Phase 1 Trial of VK2735 Begins for Metabolic Disorders
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; Enrollment Advancing for Ongoing Trials; Novel Candidates Inflate Metabolic Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Recap - VK2809 Enrollment Completion Targeted for 1H22
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
VK0214 - Optimism For Mid-2022 Clinical Validation
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
VK2014 Meets Expectations in Phase 1 and Moves to X-ALD Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Competitor''s Phase 2b Failure in NASH Adds Important Learnings; VK2809 Remains a Leader
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Results; VK2809 and VK2014 Programs on Track to Deliver Key Updates in 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Recap - VK2809 Enrollment Completion on Track for 2H21
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2020 Results; VK0214 in X-ALD Gains Visibility in 2021 While Waiting for VOYAGE
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J